Results 51 to 60 of about 230,574 (171)

Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy [PDF]

, 2012
BACKGROUND: Optimal doses of i.v. glucocorticoids for Graves' orbitopathy (GO) are undefined. METHODS: We carried out a multicenter, randomized, double-blind trial to determine efficacy and safety of three doses of i.v. methylprednisolone in 159 patients
Bernard M, for the European Group on Graves' Orbitopathy, Soeters, M R, Currò N, Nardi, M, Mourits, M P, Salvi M, Boboridis KG, Stahl, M, Daumerie C, Azzolini, C, Sassi, L, Boschi A, MARCOCCI, CLAUDIO, Currò, N, Wiersinga W, von Arx, G, Bournaud C, Boboridis, K G, Stahl M, Bartalena L, BALDESCHI, LELIO, Veronesi, G, Baldeschi, L, Krassas GE, Krassas G, Baldeschi L, Veronesi G, Boschi, Antonella, VERONESI, GIOVANNI, Marcocci, C, SASSI, LORENZA, Azzolini C, Mourits MP, Nardi M, Wiersinga, W, AZZOLINI, CLAUDIO, NARDI, MARCO, Bernard, M, for the European Group on Graves Orbitopathy, von Arx G, European Group on Graves' Orbitopathy, Marcocci C, Daumerie, Chantal, Wiersinga WM, BARTALENA, LUIGI, Bournaud, C, Salvi, M, Soeters MR, Sassi L, Curr? N, Krassas, G E, Bartalena, L   +52 more
core   +1 more source

Effectiveness of Selenium Supplementation in the Treatment of Graves–Basedow Disease: A Scoping Review

Medical Sciences
Background: Graves–Basedow disease (GBD) is an autoimmune thyroid disorder characterized by loss of tolerance to the thyrotropin receptor, with clinical manifestations such as a hyperadrenergic state, goiter, orbitopathy, and myxedema, inter alia ...
Hernando Vargas-Uricoechea, Alejandro Castellanos-Pinedo, Karen Urrego-Noguera, María V. Pinzón-Fernández, Ivonne A. Meza-Cabrera, Hernando Vargas-Sierra   +5 more
doaj   +1 more source

Significance of HLA in Graves’ disease and Graves’ orbitopathy in Asian and Caucasian populations – a systematic review

Frontiers in Immunology, 2023
IntroductionGraves’ disease (GD) and Graves’ orbitopathy (GO) development were suspected to be HLA-related in both Asian and Caucasian populations. However, most studies were performed with application of serological methods or low resolution genetic ...
Magdalena Stasiak, Bartłomiej Stasiak, Katarzyna Zawadzka-Starczewska, Andrzej Lewiński, Andrzej Lewiński   +4 more
doaj   +1 more source

Mechanistic Pathways of Selenium in the Treatment of Graves' Disease and Graves' Orbitopathy

, 2018
Based on the role of oxidative stress in the pathogenesis of Graves' hyperthyroidism and Graves' orbitopathy, the use of the antioxidant agent selenium has been proposed and several studies on the subject have been conducted, both in vitro and in vivo ...
Leo, Marenza, Marcocci, Claudio, Marinò, Michele, Rotondo Dottore, Giovanna   +3 more
core   +1 more source

Retinal, choroidal and optic disc analysis in patients with Graves' disease with or without orbitopathy

, 2020
To compare optic disc, retinal and choroidal measurements in patients with Graves' disease with or without orbitopathy, and healthy ...
Sframeli, Angela Tindara, Rocchi, Roberto, Licari, Serena, Ionni, Ilaria, Mazzi, Barbara, Casini, Giamberto, Marinò, Michele, Rubino, Marisa, Covello, Giuseppe, Loiudice, Pasquale, Figus, Michele   +10 more
core   +1 more source

Neural Network-Based Pipeline With High-Resolution Feature Enhancement and Low-Resolution Feature Preservation for Automated Treatment Decision of Graves’ Orbitopathy Patients

IEEE Access
Graves’ orbitopathy is an inflammatory disorder that causes changes in different structures close to the eye. Accurate and consistent diagnoses are essential to improve the quality of life for Graves’ orbitopathy patients.
Sanghyuck Lee, Mohd Asyraf Zulkifley, Jeong Kyu Lee, Jaesung Lee   +3 more
doaj   +1 more source

GRAVES' ORBITOPATHY: AN UPDATED REVIEW OF PATHOGENESIS, CLINICAL FEATURES, AND TREATMENT STRATEGIES [PDF]

Graves’ orbitopathy (GO) otherwise known as thyroid ophthalmopathy or thyroid eye disease (TED) is an ocular disorder that involves autoimmune inflammation of the soft tissues of the orbit.
Konrad Kotte, Olaf Jadanowski, Bartosz Komsta, Przemysław Piskorz, Kamil Łebek, Daria Litworska-Sójka, Wojciech Pabis, Julia Lipiec, Alicja Bury, Weronika Sobota   +9 more
core   +1 more source

Statin reduces orbitopathy risk in patients with Graves’ disease by modulating apoptosis and autophagy activities

, 2016
Statins use has been associated with reduced risk for developing orbitopathy among patients with Graves’ disease. We hypothesize that statin reduces orbitopathy risk mainly by modulating both apoptosis and autophagy activities in patients with Graves ...
Ciaglia Elena, CIAGLIA, ELENA, Bifulco Maurizio, BIFULCO, Maurizio   +3 more
core   +1 more source

Graves Orbitopathy [PDF]

Journal of Osteopathic Medicine, 2020
Stefano, Natali, Paul, Shogan
openaire   +2 more sources

Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves’ orbitopathy

Thyroid Research, 2019
Background Treatment of moderate to severe Graves’ orbitopathy (GO) is based mainly on intravenous pulses of methylprednisolone. High doses of methylprednisolone can exert several adverse effects, some of which might be life-threatening. The objective of
Dorota Walasik-Szemplińska, Grzegorz Kamiński, Iwona Sudoł-Szopińska   +2 more
doaj   +1 more source